Lifecycle of an Imaging Biomarker

Lifecycle of an Imaging Biomarker: From Validation to Dissemination

Thursday, Dec. 2, 10:30 AM - 12:00 PM

Speakers are sharing perspectives on the use of quantitative imaging as a biomarker in clinical trials and providing examples of best practices.

The speakers are:
  • Jeffrey T. Yap, PhD, senior diagnostic physicist, Dana-Farber Cancer Institute in Boston;
  • Neil M. Rofsky, MD, chief, MRI, Beth Israel Deaconess Medical Center in Boston;
  • Simon K. Warfield, PhD, director, computational radiology laboratory, Children’s Hospital in Boston.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.